bridgebio-logo

Meet us at the MENA Congress for Rare Diseases

CANaspire is an open-label clinical trial of an investigational gene therapy for Canavan disease. The trial is designed to assess the safety and potential benefit of an investigational gene therapy in Canavan patients.

MENA Congress will start in

  • 00Days
  • 00Hours
  • 00Minutes
  • 00Sec

Book a meeting at the MENA Congress with our team

Genevieve Laforet
MD, PhD

Senior Vice President, Clinical Development

Mary Rohrer
RN, BSN

Director, Patient Recruitment & Retention

CONNECT WITH US

Schedule a Meeting (MENA Congress / Zoom)

Please enable JavaScript in your browser to complete this form.
Accept
By completing and submitting this form, you certify that you are a licensed healthcare professional, and that you are interested in receiving information related to the CANaspire program and/or BridgeBio Pharma. By submitting you also agree to allow BridgeBio Pharma and partners to collect the data you submit on this form, which will be stored in the United States, and to send you emails related to the topics above.

BridgeBio Pharma is committed to not distribute, sell, or rent your information. BridgeBio Pharma and third-party partners in the CANaspire program will only use the information you provide in accordance with the Privacy Policy.

How to find us at the MENA Congress - Booth #14

FOLLOW US

Designed by